Anuh Pharma Experiences Revision in Stock Evaluation Amid Mixed Financial Indicators

Anuh Pharma, a small-cap player in the pharmaceuticals and drugs sector, has recently experienced a revision in its stock evaluation by MarketsMOJO. The adjustment comes in light of the company's flat results reported for September 2024, alongside a notable decline in operating cash flow, which has reached its lowest point at Rs 12.93 crore. Additionally, the debt-to-equity ratio remains low, indicating a stable financial structure.
Despite these challenges, Anuh Pharma has demonstrated a strong return on equity of 19.5%, reflecting an attractive valuation with a price-to-book ratio of 3.6. The stock has been trading at a discount compared to its historical valuations, and over the past year, it has generated a commendable return of 21.53%, with profits increasing by 32.6%.

However, the technical indicators suggest a shift in sentiment, with the stock now positioned in a mildly bearish range. This change follows a deterioration from a previously mildly bullish trend, resulting in a negative return of -5.38% since early January 2025. Notably, Anuh Pharma has been added to MarketsMOJO's list, highlighting its market performance over the long term and near term, where it has consistently outperformed the BSE 500 index.